{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:47:47Z","timestamp":1792043267878,"version":"4.4.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100018731","name":"Jiangsu Hengrui Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"DOI":"10.1007\/s00125-026-06892-2","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:15:20Z","timestamp":1792041320000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of HRS-7535, a novel oral small-molecule glucagon-like peptide-1 receptor agonist, in participants with type 2 diabetes mellitus inadequately controlled by metformin and sodium\u2013glucose co-transporter\u00a02 inhibitors: a multicentre, randomised, double-blind, placebo-controlled, parallel-group Phase II trial"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4647-3079","authenticated-orcid":false,"given":"Mingtong","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1536-884X","authenticated-orcid":false,"given":"Weihong","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1155-2682","authenticated-orcid":false,"given":"Fang","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1179-823X","authenticated-orcid":false,"given":"Yanqin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7594-626X","authenticated-orcid":false,"given":"Liu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7810-853X","authenticated-orcid":false,"given":"Xiaochang","family":"Bin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6719-6859","authenticated-orcid":false,"given":"Xiting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7740-1238","authenticated-orcid":false,"given":"Zi","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1203-7560","authenticated-orcid":false,"given":"Danli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5516-3598","authenticated-orcid":false,"given":"Xiang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4591-8207","authenticated-orcid":false,"given":"Wei","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7694-5991","authenticated-orcid":false,"given":"Chang","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2218-8644","authenticated-orcid":false,"given":"Li","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"issue":"1 Suppl 1","key":"6892_CR1","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.2337\/dc25-S002","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee (2025) Diagnosis and classification of diabetes: standards of care in diabetes \u2013 2025. Diabetes Care 48(1 Suppl 1):S27\u2013S49. https:\/\/doi.org\/10.2337\/dc25-S002","journal-title":"Diabetes Care"},{"key":"6892_CR2","doi-asserted-by":"publisher","first-page":"15019","DOI":"10.1038\/nrdp.2015.19","volume":"1","author":"RA DeFronzo","year":"2015","unstructured":"DeFronzo RA, Ferrannini E, Groop L et al (2015) Type 2 diabetes mellitus. Nat Rev Dis Primers 1:15019. https:\/\/doi.org\/10.1038\/nrdp.2015.19","journal-title":"Nat Rev Dis Primers"},{"issue":"Suppl 1","key":"6892_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13300-019-0573-y","volume":"10","author":"V Mohan","year":"2019","unstructured":"Mohan V, Cooper ME, Matthews DR, Khunti K (2019) The standard of care in type 2 diabetes: re-evaluating the treatment paradigm. Diabetes Ther 10(Suppl 1):1\u201313. https:\/\/doi.org\/10.1007\/s13300-019-0573-y","journal-title":"Diabetes Ther"},{"issue":"1","key":"6892_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/dom.14205","volume":"23","author":"L Ji","year":"2021","unstructured":"Ji L, Chan JCN, Yu M et al (2021) Early combination versus initial metformin monotherapy in the management of newly diagnosed type 2 diabetes: an East Asian perspective. Diabetes Obes Metab 23(1):3\u201317. https:\/\/doi.org\/10.1111\/dom.14205","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"6892_CR5","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s40265-017-0694-4","volume":"77","author":"C Bianchi","year":"2017","unstructured":"Bianchi C, Daniele G, Dardano A, Miccoli R, Del Prato S (2017) Early combination therapy with oral glucose-lowering agents in type 2 diabetes. Drugs 77(3):247\u2013264. https:\/\/doi.org\/10.1007\/s40265-017-0694-4","journal-title":"Drugs"},{"issue":"8","key":"6892_CR6","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.2337\/dc18-0588","volume":"41","author":"MJB van Baar","year":"2018","unstructured":"van Baar MJB, van Ruiten CC, Muskiet MHA, van Bloemendaal L, IJzerman RG, van Raalte DH (2018) SGLT2 Inhibitors in combination therapy: from mechanisms to clinical considerations in type 2 diabetes management. Diabetes Care 41(8):1543\u20131556. https:\/\/doi.org\/10.2337\/dc18-0588","journal-title":"Diabetes Care"},{"issue":"7","key":"6892_CR7","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1111\/dom.15596","volume":"26","author":"Y Wang","year":"2024","unstructured":"Wang Y, Jiang C, Dong X et al (2024) Combination of retagliptin and henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: a multicentre, randomized, double-blind, active-controlled, phase 3 trial. Diabetes Obes Metab 26(7):2774\u20132786. https:\/\/doi.org\/10.1111\/dom.15596","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"6892_CR8","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1038\/s41591-023-02502-5","volume":"29","author":"DK Tobias","year":"2023","unstructured":"Tobias DK, Merino J, Ahmad A et al (2023) Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine. Nat Med 29(10):2438\u20132457. https:\/\/doi.org\/10.1038\/s41591-023-02502-5","journal-title":"Nat Med"},{"issue":"1 Suppl 1","key":"6892_CR9","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.2337\/dc25-S004","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee (2025) 4. Comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes \u2013 2025. Diabetes Care 48(1 Suppl 1):S59\u2013S85. https:\/\/doi.org\/10.2337\/dc25-S004","journal-title":"Diabetes Care"},{"key":"6892_CR10","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","volume":"30","author":"TD M\u00fcller","year":"2019","unstructured":"M\u00fcller TD, Finan B, Bloom SR et al (2019) Glucagon-like peptide 1 (GLP-1). Mol Metab 30:72\u2013130. https:\/\/doi.org\/10.1016\/j.molmet.2019.09.010","journal-title":"Mol Metab"},{"issue":"5","key":"6892_CR11","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/s2213-8587(18)30023-8","volume":"6","author":"B Ludvik","year":"2018","unstructured":"Ludvik B, Fr\u00edas JP, Tinahones FJ et al (2018) Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 6(5):370\u2013381. https:\/\/doi.org\/10.1016\/s2213-8587(18)30023-8","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"6892_CR12","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/s2213-8587(19)30066-x","volume":"7","author":"B Zinman","year":"2019","unstructured":"Zinman B, Bhosekar V, Busch R et al (2019) Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 7(5):356\u2013367. https:\/\/doi.org\/10.1016\/s2213-8587(19)30066-x","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"6892_CR13","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1111\/dom.13978","volume":"22","author":"L Blonde","year":"2020","unstructured":"Blonde L, Belousova L, Fainberg U et al (2020) Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 22(6):929\u2013937. https:\/\/doi.org\/10.1111\/dom.13978","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"6892_CR14","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1111\/dom.15185","volume":"25","author":"DR Riley","year":"2023","unstructured":"Riley DR, Essa H, Austin P et al (2023) All-cause mortality and cardiovascular outcomes with sodium-glucose co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes. Diabetes Obes Metab 25(10):2897\u20132909. https:\/\/doi.org\/10.1111\/dom.15185","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"6892_CR15","doi-asserted-by":"publisher","first-page":"101594","DOI":"10.1016\/j.diabet.2024.101594","volume":"51","author":"AJ Scheen","year":"2025","unstructured":"Scheen AJ (2025) Cardiovascular and renal effects of the combination therapy of a GLP-1 receptor agonist and an SGLT2 inhibitor in observational real-life studies. Diabetes Metab 51(1):101594. https:\/\/doi.org\/10.1016\/j.diabet.2024.101594","journal-title":"Diabetes Metab"},{"key":"6892_CR16","doi-asserted-by":"publisher","first-page":"e64899","DOI":"10.2196\/64899","volume":"14","author":"NS Holdt-Caspersen","year":"2025","unstructured":"Holdt-Caspersen NS, Dethlefsen C, Hejlesen O et al (2025) Effect of adherence to oral semaglutide on glycemic control in people with type 2 diabetes treated with metformin: protocol for an open-label clinical trial. JMIR Res Protoc 14:e64899. https:\/\/doi.org\/10.2196\/64899","journal-title":"JMIR Res Protoc"},{"issue":"1","key":"6892_CR17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1001\/jama.2025.7761","volume":"334","author":"S Anderer","year":"2025","unstructured":"Anderer S (2025) FDA accepts application for oral version of Wegovy. JAMA 334(1):12. https:\/\/doi.org\/10.1001\/jama.2025.7761","journal-title":"JAMA"},{"issue":"10400","key":"6892_CR18","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/s0140-6736(23)01302-8","volume":"402","author":"JP Frias","year":"2023","unstructured":"Frias JP, Hsia S, Eyde S et al (2023) Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet 402(10400):472\u2013483. https:\/\/doi.org\/10.1016\/s0140-6736(23)01302-8","journal-title":"Lancet"},{"issue":"3","key":"6892_CR19","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1111\/dom.15383","volume":"26","author":"J Wu","year":"2024","unstructured":"Wu J, Zhou R, Zhang Q et al (2024) Safety, pharmacokinetics and pharmacodynamics of HRS-7535, a novel oral small molecule glucagon-like peptide-1 receptor agonist, in healthy participants: a phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose, and food effect trial. Diabetes Obes Metab 26(3):901\u2013910. https:\/\/doi.org\/10.1111\/dom.15383","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"6892_CR20","doi-asserted-by":"publisher","first-page":"e2615622","DOI":"10.1001\/jamanetworkopen.2026.15622","volume":"9","author":"L Guo","year":"2026","unstructured":"Guo L, Sun Z, Zhang L et al (2026) HRS-7535 for type 2 diabetes inadequately controlled with metformin: a randomized clinical trial. JAMA Netw Open 9(6):e2615622. https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.15622","journal-title":"JAMA Netw Open"},{"issue":"8","key":"6892_CR21","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1111\/dom.14389","volume":"23","author":"J Weng","year":"2021","unstructured":"Weng J, Zeng L, Zhang Y et al (2021) Henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: a multicentre, randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Obes Metab 23(8):1754\u20131764. https:\/\/doi.org\/10.1111\/dom.14389","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"6892_CR22","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/cpdd.1193","volume":"12","author":"Y Liu","year":"2023","unstructured":"Liu Y, Huyan X, Zhang Q et al (2023) Effects of food and multiple-dose administration on the pharmacokinetic properties of HR20033, a sustained-release formulation of henagliflozin and metformin for the treatment of diabetes, in healthy Chinese volunteers. Clin Pharmacol Drug Dev 12(4):376\u2013384. https:\/\/doi.org\/10.1002\/cpdd.1193","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"4","key":"6892_CR23","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s13300-020-00994-9","volume":"12","author":"RE Pratley","year":"2021","unstructured":"Pratley RE, Crowley MJ, Gislum M et al (2021) Oral semaglutide reduces HbA1c and body weight in patients with type 2 diabetes regardless of background glucose-lowering medication: PIONEER subgroup analyses. Diabetes Ther 12(4):1099\u20131116. https:\/\/doi.org\/10.1007\/s13300-020-00994-9","journal-title":"Diabetes Ther"},{"issue":"11","key":"6892_CR24","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1056\/NEJMoa2505669","volume":"393","author":"J Rosenstock","year":"2025","unstructured":"Rosenstock J, Hsia S, Nevarez Ruiz L et al (2025) Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes. N Engl J Med 393(11):1065\u20131076. https:\/\/doi.org\/10.1056\/NEJMoa2505669","journal-title":"N Engl J Med"},{"issue":"10550","key":"6892_CR25","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/s0140-6736(26)00800-7","volume":"408","author":"M Welch","year":"2026","unstructured":"Welch M, Forst T, Jia W et al (2026) Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial. Lancet 408(10550):125\u2013140. https:\/\/doi.org\/10.1016\/s0140-6736(26)00800-7","journal-title":"Lancet"},{"issue":"10534","key":"6892_CR26","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/s0140-6736(26)00202-3","volume":"407","author":"J Rosenstock","year":"2026","unstructured":"Rosenstock J, Yabe D, Cox D et al (2026) Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. Lancet 407(10534):1147\u20131160. https:\/\/doi.org\/10.1016\/s0140-6736(26)00202-3","journal-title":"Lancet"},{"issue":"Suppl 1","key":"6892_CR27","doi-asserted-by":"publisher","first-page":"837-P","DOI":"10.2337\/db25-837-P","volume":"74","author":"L Guo","year":"2025","unstructured":"Guo L, Sun Z, Zhang L et al (2025) 837-P: efficacy and safety of a novel oral small molecule glucagon-like peptide\u00a01 receptor agonist (HRS-7535) in type 2 diabetes mellitus patients inadequately controlled by metformin. Diabetes 74(Suppl 1):837-P. https:\/\/doi.org\/10.2337\/db25-837-P","journal-title":"Diabetes"},{"issue":"1","key":"6892_CR28","doi-asserted-by":"publisher","first-page":"7867","DOI":"10.1038\/s41467-026-73018-y","volume":"17","author":"W Gu","year":"2026","unstructured":"Gu W, Zhang L, Li L et al (2026) HRS-7535, an oral small-molecule GLP-1 receptor agonist, in Chinese adults with obesity without diabetes: a randomized, double-blind, placebo-controlled phase 2 trial. Nat Commun 17(1):7867. https:\/\/doi.org\/10.1038\/s41467-026-73018-y","journal-title":"Nat Commun"},{"issue":"1","key":"6892_CR29","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41591-025-04057-z","volume":"32","author":"HJL Heerspink","year":"2026","unstructured":"Heerspink HJL, Collier WH, Chaudhari J et al (2026) A meta-analysis of albuminuria as a surrogate endpoint for kidney failure. Nat Med 32(1):281\u2013287. https:\/\/doi.org\/10.1038\/s41591-025-04057-z","journal-title":"Nat Med"},{"key":"6892_CR30","doi-asserted-by":"publisher","unstructured":"Du XL, Rong Lv, Ye Zi et al (2025) Efficacy and safety of the oral small-molecule GLP-1 receptor agonist HRS-7535 in patients with diabetic kidney disease. J Am Soc Nephrol 36(10S). https:\/\/doi.org\/10.1681\/ASN.20254m6bwa9n","DOI":"10.1681\/ASN.20254m6bwa9n"},{"issue":"2","key":"6892_CR31","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.eprac.2023.11.007","volume":"30","author":"HUH Ansari","year":"2024","unstructured":"Ansari HUH, Qazi SU, Sajid F et al (2024) Efficacy and safety of glucagon-like peptide-1 receptor agonists on body weight and cardiometabolic parameters in individuals with obesity and without diabetes: a systematic review and meta-analysis. Endocr Pract 30(2):160\u2013171. https:\/\/doi.org\/10.1016\/j.eprac.2023.11.007","journal-title":"Endocr Pract"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-026-06892-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-026-06892-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-026-06892-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:15:22Z","timestamp":1792041322000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-026-06892-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":31,"alternative-id":["6892"],"URL":"https:\/\/doi.org\/10.1007\/s00125-026-06892-2","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,14]]},"assertion":[{"value":"20 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Medical writing assistance was provided by J. Du (medical writer at Jiangsu Hengrui Pharmaceuticals) according to good publication practice guidelines. We thank clinical trial participants and their caregivers, without whom this work would not have been possible. Preliminary results were presented in part at the EASD 61st Annual Meeting, Vienna, Austria, 15\u201319 September 2025.","order":1,"name":"Ethics","label":"Acknowledgements","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures and electronic supplementary material [ESM]), will be made available to researchers who provide a methodologically sound proposal. The study protocol, statistical analysis plan and informed consent form will also be available. Data will be available starting from 6 months and ending 5 years after article publication. Proposals should be directed to the corresponding author, and a data access agreement will be required before data release. Data requests are subject to approval by the trial sponsor (Jiangsu Hengrui Pharmaceuticals).","order":2,"name":"Ethics","label":"Data availability","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The study was sponsored by Jiangsu Hengrui Pharmaceuticals. The trial was jointly designed by the principal investigator and the sponsor. Both the authors and the sponsor were involved in data collection, analysis and interpretation. They also ensured the accuracy and completeness of the data, contributed to the writing of the report, and participated in the decision to submit the findings for publication.","order":3,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"LYan, MX, WS, FL, YF, LYang, XB and XZ report having received consulting and speaker fees from Jiangsu Hengrui Pharmaceuticals Co. Ltd. ZY, DZ, XL, WD and CS are employees of Jiangsu Hengrui Pharmaceuticals Co. Ltd. The authors declare that there are no other relationships or activities that might bias, or be perceived to bias, their work.","order":4,"name":"Ethics","label":"Authors\u2019 relationships and activities","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"LYan contributed to the study design. MX and WS provided medical oversight during the trial. FL, YF, LYang, XB and XZ were the clinical research scientists. ZY and DZ provided methodological guidance. CS was responsible for the pharmacokinetic analyses. XL and WD were responsible for the statistical analyses. MX wrote the first draft with medical writing support. All authors participated in interpretation of the data and critical review of the manuscript, had full access to the data, and approved this manuscript for submission for publication. LYan is the guarantor of this work, and, as such, takes responsibility for the integrity of the data and the accuracy of the data analysis.","order":5,"name":"Ethics","label":"Contribution statement","group":{"name":"EthicsHeading","label":"Ethics"}}]}}